GIP and diabetes mellitus: Tirzepatide, a dual GIP and GLP-1 receptor agonist, has recently been approved for the treatment of patients with diabetes [9,10,11]; it has resulted in superior HbA1c reduction in diabetes patients and exhibited unprecedented weight loss in obese individuals compared with GLP-1 receptor agonists alone.